2019
DOI: 10.1200/jco.2019.37.15_suppl.e17101
|View full text |Cite
|
Sign up to set email alerts
|

Half-dose olaparib reduction: Safe and efficient dose in multi-treated Mexican ovarian cancer patients.

Abstract: e17101 Background: Ovarian cancer (OC) is the most common gynecological cancer worldwide, and in Mexico stands as the 2nd gynecological cancer-related death cause with 4,759 new cases yearly. PARP inhibitors in BRCA1/2 mutated patients offer disease control after response to chemotherapy with few side effects and minimal impact on quality of life. The primary objective of this study was to evaluate the clinical benefit of Olaparib half-dose reduction in multi-treated Mexican OC patients. Methods: Nineteen OC … Show more

Help me understand this report

This publication either has no citations yet, or we are still processing them

Set email alert for when this publication receives citations?

See others like this or search for similar articles